What is the recommended preparation and dosage of combined aluminum hydroxide and magnesium hydroxide antacid for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Aluminum and Magnesium Hydroxide Antacid Dosing

For adults, the standard dose of combined aluminum and magnesium hydroxide antacid is 1.425-2.85 g of aluminum hydroxide daily (typically divided into multiple doses), often combined with magnesium hydroxide in ratios ranging from 1:0.6 to 1:3.5 to balance the constipating effects of aluminum with the laxative effects of magnesium. 1, 2

Adult Dosing

Standard therapeutic dosing:

  • Aluminum hydroxide: 1.425-2.85 g per day in divided doses for phosphate binding in chronic kidney disease 1
  • Combined formulations: The ratio of aluminum oxide to magnesium hydroxide typically ranges from 1:0.6 to 1:3.5, allowing selection based on desired gastrointestinal effects 2
  • For heartburn/reflux: Two chewable tablets of high-potency aluminum/magnesium hydroxide formulations provide effective esophageal pH control with onset of action within minutes and duration of approximately 60-82 minutes 3

Important considerations for adults:

  • Aluminum hydroxide has extensive clinical experience in CKD and ESRD, though aluminum accumulates in bone and neural tissue with long-term use 1
  • The bioavailability of mycophenolic acid may be reduced by aluminum/magnesium hydroxide-containing antacids, requiring dose separation 1
  • Contraindication: Aluminum hydroxide is not recommended when GFR < 35 mL/min/1.73 m² due to accumulation risk 1

Pediatric Dosing

For gastroesophageal reflux in children:

  • 700 mmol/1.73 m²/day of combined aluminum and magnesium hydroxide administered for 8 weeks showed significant efficacy in reducing reflux episodes 4
  • This translates to approximately 15-20 mL of standard suspension (containing ~200-400 mg aluminum hydroxide and 200-400 mg magnesium hydroxide per 5 mL) given 3-4 times daily for a typical child 4

Critical pediatric safety considerations:

  • Aluminum-based phosphate binders should be limited to 1-2 days in children to avoid cumulative aluminum toxicity 1
  • Aluminum hydroxide dose: 50-150 mg/kg/day divided every 6 hours for hyperphosphatemia, but use should be restricted to 1-2 days maximum 1
  • Alternative phosphate binders (calcium carbonate, sevelamer, lanthanum) should be considered for longer-term use in children 1

Administration Guidelines

Optimal timing and preparation:

  • Antacids should be taken 1 hour after meals for heartburn/reflux to maximize esophageal contact time 3
  • Shake suspensions well before use to ensure uniform distribution of active ingredients 2
  • Separate administration from other medications by at least 2 hours to avoid drug interactions, particularly with antibiotics, bisphosphonates, and immunosuppressants 1

Formulation considerations:

  • Aluminum/magnesium hydroxide combinations demonstrate superior esophageal pH control compared to calcium carbonate, with faster onset and longer duration of action 3
  • High-potency formulations provide more consistent acid-neutralizing capacity with smaller volumes 2, 3

Critical Safety Warnings

Absolute contraindications:

  • Severe renal impairment (GFR < 35 mL/min/1.73 m²) due to aluminum accumulation risk 1
  • Concurrent use with azathioprine and allopurinol requires extreme caution or avoidance 1

Monitoring requirements:

  • Assess renal function before initiating aluminum-containing antacids 1
  • Monitor for signs of aluminum toxicity with prolonged use: encephalopathy, bone disease, anemia 1
  • Watch for gastrointestinal effects: constipation (aluminum) versus diarrhea (magnesium) 2

Drug interactions requiring dose adjustment:

  • Mycophenolate mofetil bioavailability reduced; separate dosing by 2+ hours 1
  • Bisphosphonates: avoid concurrent administration 1
  • Fluoroquinolones and tetracyclines: significantly reduced absorption 1

Duration of Therapy

Short-term use (preferred):

  • For acute symptoms: use as needed, typically not exceeding 2 weeks without medical evaluation 3
  • For hyperphosphatemia in children: limit to 1-2 days maximum to prevent aluminum toxicity 1

Long-term considerations:

  • If chronic use is necessary, consider non-aluminum alternatives (calcium carbonate, magnesium carbonate, or newer agents like sevelamer) 1
  • In CKD patients requiring phosphate binding, aluminum hydroxide remains cost-effective but requires careful monitoring for toxicity 1

Related Questions

What is Almagel, its composition, indications, recommended dosing, and safety precautions?
What is the comparison between Magnesium carbonate/Aluminum hydroxide/Alginate, Magnesium hydroxide/Aluminum hydroxide/Simethicone, and Phenobarbital/Hyoscyamine/Atropine/Scopolamine?
What is the recommended dose of aluminum hydroxide (Al(OH)3) and magnesium hydroxide (Mg(OH)2)?
Does aluminum and magnesium hydroxide interfere with the activity of pregabalin?
What is the recommended dosage of Mylanta (aluminum hydroxide, magnesium hydroxide, and simethicone) for adults and children over 12 years old?
What is the recommended management for a 29‑day‑old neonate with confirmed or suspected SARS‑CoV‑2 infection?
For a reproductive‑age woman with one prior low‑transverse cesarean delivery and no contraindications (no classical scar, no multiple prior cesareans, no placenta previa, no active genital herpes, no fetal macrosomia), should she be offered a trial of labour after cesarean (vaginal birth after cesarean) and what are the recommended management steps?
What is the mechanism of action of caffeine in treating apnea of prematurity in preterm infants?
In an older adult with gait disturbance, dysphagia, and recurrent falls, what urgent work‑up and management steps are recommended?
How should basal atelectasis be managed in a postoperative, immobile patient with shallow breathing?
What are the recommended interpretation and management steps for cardiotocography (CTG) in a term (≥37 weeks) laboring patient, including how to handle Category I, Category II, and Category III tracings and any maternal conditions such as pre‑eclampsia, diabetes, or anemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.